BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16115232)

  • 21. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
    Zuo T; Wong S; Buza N; Hui P
    Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology of borderline (low malignant potential) ovarian tumours.
    Seidman JD; Ronnett BM; Kurman RJ
    Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):499-512. PubMed ID: 12413931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
    PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
    Evans MF; McDicken IW; Herrington CS
    J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular carcinogenesis of ovarian carcinoma].
    Diebold J
    Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro fertilization following conservative management of stage 3 serous borderline tumor of the ovary.
    Hoffman JS; Laird L; Benadiva C; Dreiss R
    Gynecol Oncol; 1999 Sep; 74(3):515-8. PubMed ID: 10479523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.
    Bürger T; Schildhaus HU; Inniger R; Hansen J; Mayer P; Schweyer S; Radzun HJ; Ströbel P; Bremmer F
    Diagn Pathol; 2015 Jul; 10():118. PubMed ID: 26197800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micropapillary pattern in serous borderline ovarian tumors: does it matter?
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2011 Dec; 123(3):511-6. PubMed ID: 21917305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
    Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
    Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
    Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian tumours: a study of 282 cases.
    Pilli GS; Suneeta KP; Dhaded AV; Yenni VV
    J Indian Med Assoc; 2002 Jul; 100(7):420, 423-4, 447. PubMed ID: 12674165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI appearances of borderline ovarian tumours.
    Bent CL; Sahdev A; Rockall AG; Singh N; Sohaib SA; Reznek RH
    Clin Radiol; 2009 Apr; 64(4):430-8. PubMed ID: 19264189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mutational profile of sporadic epithelial ovarian carcinoma.
    Kalamanathan S; Bates V; Lord R; Green JA
    Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).
    Kadar N; Krumerman M
    Gynecol Oncol; 1995 Dec; 59(3):394-7. PubMed ID: 8522262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetic analysis of ovarian serous cystadenomas.
    Cheng EJ; Kurman RJ; Wang M; Oldt R; Wang BG; Berman DM; Shih IeM
    Lab Invest; 2004 Jun; 84(6):778-84. PubMed ID: 15077125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology.
    Dietel M; Hauptmann S
    Virchows Arch; 2000 May; 436(5):403-12. PubMed ID: 10881733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.